Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Other Non-Current Assets: 2014-2024

Historic Other Non-Current Assets for ImmunityBio (IBRX) over the last 11 years, with Dec 2024 value amounting to $4.4 million.

  • ImmunityBio's Other Non-Current Assets rose 22.78% to $4.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.5 million, marking a year-over-year increase of 22.78%. This contributed to the annual value of $4.4 million for FY2024, which is 54.48% up from last year.
  • Per ImmunityBio's latest filing, its Other Non-Current Assets stood at $4.4 million for FY2024, which was up 54.48% from $2.9 million recorded in FY2023.
  • Over the past 5 years, ImmunityBio's Other Non-Current Assets peaked at $6.8 million during FY2021, and registered a low of $2.6 million during FY2020.
  • Over the past 3 years, ImmunityBio's median Other Non-Current Assets value was $4.4 million (recorded in 2024), while the average stood at $4.1 million.
  • Its Other Non-Current Assets has fluctuated over the past 5 years, first slumped by 40.77% in 2020, then spiked by 160.78% in 2021.
  • ImmunityBio's Other Non-Current Assets (Yearly) stood at $2.6 million in 2020, then skyrocketed by 160.78% to $6.8 million in 2021, then decreased by 28.27% to $4.9 million in 2022, then plummeted by 40.74% to $2.9 million in 2023, then spiked by 54.48% to $4.4 million in 2024.